The randomized, controlled study of the device, dubbed “Protect”, is slated to launch in winter and aims to enroll 242 patients to examine the use of the device for treating OAB. The trial will examine the effectiveness of pulsed electrical energy delivered to the tibial nerve...
The FDA gave its blessing to the Saint system from Magnus Medical, which uses patient scans to direct neurostimulation therapy to the area of the brain where it may be most effective. With the 510(k) clearance from the agency, Magnus will aim to begin rolling out the system “lat...
Phantom Neuro received FDA breakthrough device designation and TAP designation for its minimally invasive neural interface Phantom X.